



Drug recall for Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL vials

On August 10, 2026, Fresenius Kabi announced that it is voluntarily withdrawing Tyenne® (tocilizumab-aazg) from the US market due to presence of glass particles in the affected lots.

Please carefully review the impacted medication and talk to your doctor about it right away.

What this means to you:

- Check your medication label for the drug name and company name. If you aren't sure if you have the recalled medication, check with the pharmacy where you picked up your prescription.
- Do not stop taking your medication. Talk to your doctor first. You may be able to switch to another drug or get the same drug that is not part of the recall.
- Please go to <https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/fresenius-kabi-issues-nationwide-recall-tyenner-tocilizumab-aazg-injection-400-mg20-ml-vials-due> for the most current news on this drug recall.
- Call Fresenius Kabi USA Quality Assurance at 1-866-716-2459, Monday through Friday, during the hours of 8:00 a.m. to 5:00 p.m., Central Time, if you have questions.

If you have any problems with this drug:

- Report them to the FDA's MedWatch Adverse Event Reporting program.
 - **Online:** You can fill out the report at <https://www.accessdata.fda.gov/scripts/medwatch>
 - Select Consumer/Patient (FDA Form 3500B)
 - **Regular mail or fax:** Download the form at www.fda.gov/media/85598/download
 - Form FDA-3500B: Consumer Voluntary Reporting will automatically download
 - To have a form mailed to you, call 800-332-1088 (TTY:711). Complete the form and send it back to the address on the form. Or fax it to 800-FDA-0178.

If you have questions about this medicine or the recall, please talk to your doctor or pharmacist. You may also call the number on the back of your Humana member ID card.

For 24-hour service, you can sign into MyHumana, your personal, secure online account on Humana.com, to search for other medicine that your plan covers.

As your partner in health, we want to make sure that you are informed about issues that may affect your health and overall well-being.

Source

“Fresenius Kabi Issues Nationwide Recall of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials Due to Presence of Glass Particles,” U.S. Food and Drug Administration, last accessed Aug. 11, 2026. <https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/fresenius-kabi-issues-nationwide-recall-tyenner-tocilizumab-aazg-injection-400-mg20-ml-vials-due>